Metabolic differences in women with premature ovarian insufficiency: a systematic review and meta-analysis

Cai, Wei-Xiong; Luo, Xi; Wu, Wei; Song, Junxian; Xie, Na; Duan, Cuicui; Wu, Xiao-Ke; Xu, Jian

doi:10.1186/s13048-022-01041-w

Cited by 10 publications

(5 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no significant difference between groups in HDL-C levels or apo AI kinetic parameters. The latter results show that menopausal status adversely affects LDL-C levels and kinetics, 54,60,61 unlike the findings from eumenorrheic women. These results raise questions about the reliability of preclinical studies to infer results in human populations.…”

Section: Kinetic Studies Focused On Vldl/ldl Particlesmentioning

confidence: 56%

Sex-Specific Differences in Lipoprotein Production and Clearance

Conlon

Welty²,

Reyes‐Soffer

et al. 2023

ATVB

View full text Add to dashboard Cite

Therapeutic approaches to reduce atherogenic lipid and lipoprotein levels remain the most effective and assessable strategies to prevent and treat cardiovascular disease. The discovery of novel research targets linked to pathways associated with cardiovascular disease development has enhanced our ability to decrease disease burden; however, residual cardiovascular disease risks remain. Advancements in genetics and personalized medicine are essential to understand some of the factors driving residual risk. Biological sex is among the most relevant factors affecting plasma lipid and lipoprotein profiles, playing a pivotal role in the development of cardiovascular disease. This minireview summarizes the most recent preclinical and clinical studies covering the effect of sex on plasma lipid and lipoprotein levels. We highlight the recent advances in the mechanisms regulating hepatic lipoprotein production and clearance as potential drivers of disease presentation. We focus on using sex as a biological variable in studying circulating lipid and lipoprotein levels.

show abstract

Section: Kinetic Studies Focused On Vldl/ldl Particlesmentioning

confidence: 56%

Sex-Specific Differences in Lipoprotein Production and Clearance

Conlon

Welty²,

Reyes‐Soffer

et al. 2023

ATVB

View full text Add to dashboard Cite

show abstract

“…PM or EM is accompanied by abnormal glucose and lipid metabolism, which are independent and important cardiovascular risk factors. A meta-analysis included 21 studies reported that earlier menopause was linked to significantly higher lipid and glucose levels ( 41 ). Also, hyperandrogenism and low sex hormone-binding globulin are involved in the development of CVDs ( 42 ).…”

Section: Discussionmentioning

confidence: 99%

“…This is the primary limitation of our study and other studies have examined the association between earlier menopause and the increased risk of CVD. Moderate heterogeneity (I 2 > 50%) existed in the systematic review for T2D, HT, CHD (<40), stroke (40)(41)(42)(43)(44)(45), ischemic stroke (40)(41)(42)(43)(44)(45). Considerable heterogeneity (I 2 > 70%) existed for stroke (<40), Forest plot presents the association between PM or EM and the risk of stroke in cohort study.…”

Section: Strengths and Limitationsmentioning

confidence: 99%

The risk of long-term cardiometabolic disease in women with premature or early menopause: A systematic review and meta-analysis

Liu

Jin

Liu

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundTransition into menopause is associated with an increased risk of cardiovascular disease (CVD). However, it is unclear whether the association exists between premature menopause (defined as age at menopause 40 years) or early menopause (defined as age at menopause 40–45 years) and CVD or cardiovascular risk factors. The aim of this review was to comprehensively evaluate and meta-analyze the most reliable evidence about the relationship between menopausal age and the risk of long-term cardiometabolic disease.MethodsA comprehensive literature search of the PubMed, Web of Science, and Embase databases from inception to October 1, 2022, for titles and abstracts with a restriction to English language papers led to the discovery of the studies. Data are expressed as the Hazard Ratio (HR) with 95% confidence intervals (CI). The degree of heterogeneity was measured using the I-square (I2) index.Results921,517 participants from 20 cohort studies published between 1998 and 2022 were considered. Compared to women with menopause at age >45 years, women with premature menopause (PM) or early menopause (EM) had a higher risks of type 2 diabetes (RR: 1.32, 95% CI: 1.08–1.62; RR: 1.11, 95% CI: 0.91–1.36, respectively), hyperlipidemia (RR: 1.21, 95% CI: 1.05–1.39; RR: 1.17, 95% CI: 1.02–1.33, respectively), coronary heart disease (RR: 1.52, 95% CI: 1.22–1.91; RR: 1.19, 95% CI: 1.07–1.32, respectively), stroke (RR: 1.27, 95% CI: 1.02–1.58; RR: 1.13, 95% CI: 0.97–1.32, respectively) and total cardiovascular event (RR: 1.36, 95% CI: 1.16–1.60; RR: 1.14, 95% CI: 0.97–1.35, respectively). No difference was found for hypertension in PM or EM women (RR: 0.98, 95% CI: 0.89–1.07; RR: 0.97, 95% CI: 0.91–1.04, respectively). Additionally, we also found that PM women, but not EM women, were linked with an increased risk of ischemic and hemorrhagic stroke. However, this is not in line with the conclusion that both PM and EM had a higher risk of total stroke.ConclusionWomen with PM or EM have a higher risk of developing long-term CVD, compared to women with menopause at age >45 years. Therefore, we recommend early lifestyle interventions (e.g., maintaining a healthy lifestyle) and medical treatments (e.g., timely initiation of menopausal hormone therapy) to decrease the risk of cardiometabolic disease in early or premature menopausal women.Systematic Review RegistrationPROSPERO, identifier CRD42022378750

show abstract

“…According to these authors, analysis between POI women using and not using hormone therapy was not available because most included studies didn't mention whether the women used hormone therapy, which reinforce that our results can collaborate to reduce the gap in the evidences. 35 All women were using HT and were matched by age and BMI to control group women, which are confounding factors that can influence the variables that were analyzed. Furthermore, women diagnosed with previous comorbidities that have a potential cardiovascular risk were not excluded to avoid an important selection bias.…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular Risk Factors in Premature Ovarian Insufficiency using Hormonal Therapy

Rezende

Dassie

Yela

et al. 2023

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

Objective Premature ovarian insufficiency (POI) is characterized by early hypoestrogenism. An increased risk of cardiovascular (CV) disease is a long-term consequence of POI. A challenge of hormone therapy (HT) is to reduce the CV risk. Methods Cross-sectional study with lipid profile analysis (total cholesterol, LDL-C, HDL-C, VLDL-C and triglycerides), blood glucose levels and arterial blood pressure of women with POI using HT, compared with age and BMI-matched women with normal ovarian function (controls). Results The mean age and BMI of 102 POI patients using HT and 102 controls were 37.2 ± 6.0 and 37.3 ± 5.9 years, respectively; 27.0 ± 5.2 and 27.1 ± 5.4 kg/m2. There wasn't difference between groups in arterial systolic and diastolic blood pressure, blood glucose levels, total cholesterol, LDL-C, VLDL-C and triglycerides. HDL-C levels were significantly higher in the POI group (56.3 ± 14.6 and 52 ± 13.9mg/dL; p = 0.03). Arterial hypertension was the most prevalent chronic disease (12% in the POI group, 19% in the control group, p = ns), followed by dyslipidemia (6 and 5%, in POI and control women). Conclusion Women with POI using HT have blood pressure levels, lipid and glycemic profile and prevalence of hypertension and dyslipidemia similar to women of the same age and BMI with preserved gonadal function, in addition to better HDL levels.

show abstract

Metabolic differences in women with premature ovarian insufficiency: a systematic review and meta-analysis

Cited by 10 publications

References 68 publications

Sex-Specific Differences in Lipoprotein Production and Clearance

Sex-Specific Differences in Lipoprotein Production and Clearance

The risk of long-term cardiometabolic disease in women with premature or early menopause: A systematic review and meta-analysis

Cardiovascular Risk Factors in Premature Ovarian Insufficiency using Hormonal Therapy

Contact Info

Product

Resources

About